| Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. | |
| | |
MedLine Citation:
|
PMID: 17656219 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To assess the prognostic effect of perineural invasion (PNI) for patients undergoing external beam radiotherapy for prostate cancer. METHODS: We evaluated 657 consecutive patients who had undergone external beam radiotherapy for clinically localized prostate cancer. The clinical/treatment parameters used for analysis included PNI, clinical stage, biopsy Gleason score, pretreatment prostate-specific antigen, radiation dose, and androgen deprivation. The primary endpoint was biochemical recurrence defined by the Radiation Therapy Oncology Group-American Society for Therapeutic Radiology Oncology Phoenix consensus; the secondary endpoint was prostate cancer death. RESULTS: Of 586 men with a minimum of 24 months of follow-up, 112 (19.1%) had PNI present in the biopsy specimen. When patients were stratified into risk groups using the National Comprehensive Cancer Network criteria, PNI was more prevalent in patients within higher risk groups (6.8% in low-risk versus 18.3% in intermediate-risk versus 30.1% in high-risk groups; P <0.001). The presence of PNI was associated with lower biochemical recurrence-free (P = 0.003) and cancer-specific (P = 0.040) survival rates by Kaplan-Meier analysis. Cox regression analysis showed that PNI was a statistically significant prognostic factor of biochemical recurrence on both univariate (hazard ratio [HR] 1.71, 95% confidence interval [CI] 1.19 to 2.46, P = 0.004) and multivariate (HR 1.57, 95% CI 1.06 to 2.32, P = 0.025) analyses. Regression analysis after stratification by risk group and adjustment for treatment covariates demonstrated a significant association between PNI and the risk of biochemical recurrence for low-risk (HR 4.14, 95% CI 1.55 to 11.02, P = 0.005) and intermediate/high-risk patients (HR 1.53, 95% CI 1.02 to 2.29, P = 0.040). CONCLUSIONS: The results of our study have shown that the presence of PNI is an independent risk factor associated with an increased risk of biochemical recurrence in patients with prostate cancer undergoing external beam radiotherapy. |
| | |
Authors:
|
Hsiang-Hsuan M Yu; Danny Y Song; Ya-Yu Tsai; Travis Thompson; Deborah A Frassica; Theodore L DeWeese |
Related Documents
:
|
17391879 - Primary prevention of breast cancer: new approaches. 20517309 - Gamma-glutamyl transferase and breast cancer risk. 20838879 - Bone mineral density and risk of postmenopausal breast cancer. 179369 - Breast patterns as an index of risk for developing breast cancer. 22415519 - Epigenetic down regulation of rassf10 and its possible clinical implication in prostate... 19029399 - Mammographic breast density--evidence for genetic correlations with established breast ... 8280499 - Study of the role of breast self-examination in the reduction of mortality from breast ... 17113629 - Gagec1, a cancer/testis associated antigen family member, is a target of tgf-beta1 in a... 22198009 - A word of caution regarding napsin a expression in squamous cell carcinomas of the lung. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Urology Volume: 70 ISSN: 1527-9995 ISO Abbreviation: Urology Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-07-27 Completed Date: 2007-08-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: United States |
Other Details:
|
Languages: eng Pagination: 111-6 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland 21231-2410, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
blood,
pathology*,
radiotherapy* Aged Disease-Free Survival Humans Male Neoplasm Invasiveness Nervous System Neoplasms / blood, pathology* Prostate / innervation* Prostate-Specific Antigen / blood Prostatic Neoplasms / blood, pathology*, radiotherapy* |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from th...
Next Document: Short-term cancer control after primary cryosurgical ablation for clinically localized prostate canc...